 |
0 Diseases |  |
8 Trials |
|
8 Trials |  |
108 News |  |
| «1234 |
- ulixertinib (BVD-523) / BioMed Valley Discoveries
Trial completion: Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers (clinicaltrials.gov) - Jul 13, 2017
P1, N=6, Completed, Sponsor: BioMed Valley Discoveries, Inc
Active, not recruiting --> Completed
- | Biomarker, New P2 trial, BRCA Biomarker, PARP Biomarker, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - May 15, 2017
P2, N=568, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Biomarker, Enrollment change, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Mar 24, 2017
P2, N=6452, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=3000 --> 6452
- ulixertinib (BVD-523) / BioMed Valley Discoveries
Trial primary completion date, Metastases: BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 17, 2017
P1, N=25, Recruiting, Sponsor: Washington University School of Medicine
N=3000 --> 6452 Trial primary completion date: Dec 2017 --> Dec 2018
- ulixertinib (BVD-523) / BioMed Valley Discoveries
Trial initiation date, Trial primary completion date, Metastases: BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 16, 2017
P1, N=25, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2017 --> Dec 2018 Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Apr 2017 --> Dec 2017
- ulixertinib (BVD-523) / BioMed Valley Discoveries
Enrollment closed: Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers (clinicaltrials.gov) - Feb 7, 2017
P1, N=6, Active, not recruiting, Sponsor: BioMed Valley Discoveries, Inc
Initiation date: Mar 2016 --> Jun 2016 | Trial primary completion date: Apr 2017 --> Dec 2017 Not yet recruiting --> Active, not recruiting
- ||| ulixertinib (BVD-523) / BioMed Valley Discoveries
Enrollment closed, Metastases: Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jan 5, 2017
P1/2, N=125, Active, not recruiting, Sponsor: BioMed Valley Discoveries, Inc
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || ulixertinib (BVD-523) / BioMed Valley Discoveries
Trial primary completion date, Metastases: Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies (clinicaltrials.gov) - Oct 11, 2016
P1/2, N=125, Recruiting, Sponsor: BioMed Valley Discoveries, Inc
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Jul 2017
- ulixertinib (BVD-523) / BioMed Valley Discoveries
Enrollment open, Metastases: BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 9, 2016
P1, N=25, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Sep 2016 --> Jul 2017 Not yet recruiting --> Recruiting
- | Biomarker, Enrollment open, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Jun 9, 2016
P2, N=3000, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Dec 24, 2015
P2, N=3000, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Trial primary completion date: Aug 2021 --> Jun 2022
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Nov 24, 2015
P2, N=3000, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2021 --> Jun 2022 Trial primary completion date: Jun 2022 --> Aug 2021
- | ulixertinib (BVD-523) / BioMed Valley Discoveries
New P1 trial, Metastases: BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 18, 2015
P1, N=25, Not yet recruiting, Sponsor: Washington University School of Medicine
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Nov 6, 2015
P2, N=3000, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2022 --> Aug 2021 Recruiting --> Suspended
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Aug 17, 2015
P2, N=3000, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Not yet recruiting --> Recruiting
- Biomarker, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Jul 6, 2015
P2, N=3000, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Oct 2015 --> Jul 2015
- | Biomarker, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Jun 6, 2015
P2, N=3000, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| ulixertinib (BVD-523) / BioMed Valley Discoveries
New P1/2 trial: Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Nov 20, 2014
P1/2, N=60, Recruiting, Sponsor: BioMed Valley Discoveries, Inc
- || ulixertinib (BVD-523) / BioMed Valley Discoveries
Trial primary completion date, Metastases: Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jul 18, 2014
P1/2, N=125, Recruiting, Sponsor: BioMed Valley Discoveries, Inc
Initiation date: Oct 2015 --> Jul 2015 Trial primary completion date: Mar 2015 --> Sep 2016
- |||| ulixertinib (BVD-523) / BioMed Valley Discoveries
Enrollment open, Metastases: Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies (clinicaltrials.gov) - Apr 17, 2013
P1/2, N=120, Recruiting, Sponsor: BioMed Valley Discoveries, Inc
Trial primary completion date: Mar 2015 --> Sep 2016 Not yet recruiting --> Recruiting
- ||||| ulixertinib (BVD-523) / BioMed Valley Discoveries
New P1/2 trial, Metastases: Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies (clinicaltrials.gov) - Jan 30, 2013
P1/2, N=120, Recruiting, Sponsor: BioMed Valley Discoveries, Inc